SOHM, Inc. (OTC PINK:SHMN) announced a significant milestone in the development of its proprietary ABBIE gene editing platform, successfully demonstrating that ABBIE version 2 can effectively modify cultured human cells using advanced dCas12a technology. This achievement marks a critical advancement toward commercial-ready gene editing technology and positions the pharmaceutical company for enhanced strategic partnerships and licensing opportunities.
Enhanced Technology Platform Delivers Precision
The latest achievement represents a substantial upgrade from previous iterations, with the new dCas12a domain replacing the earlier dCas9 technology to deliver enhanced functionality and precision. The breakthrough positions SOHM to pursue simultaneous multi-target editing capabilities through crRNA arrays, potentially offering unprecedented efficiency in gene modification applications.
"This milestone validates our scientific approach and brings us significantly closer to realizing the full potential of our ABBIE platform," said Dr. David Aguilar, COO of SOHM.
Proven Applications in Drug Discovery
Complementing the core platform advancement, SOHM has successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression. These specialized cellular tools demonstrate immediate commercial applications including drug screening capabilities for targeted therapeutics such as GYS1 inhibitors, research applications for academic and pharmaceutical partnerships, and diagnostic development opportunities across multiple therapeutic areas.
The proven ability to create specialized cellular tools and modify human cells positions the company to engage with pharmaceutical partners, research institutions, and biotechnology companies seeking advanced gene editing solutions.
Strategic Market Position
The technological advancements significantly enhance SOHM's position for strategic partnerships and out-licensing opportunities. The company's licensing strategy will focus on leveraging the ABBIE platform's multi-target capabilities and proven cellular engineering applications to create value across multiple therapeutic areas and research applications.
The global genome editing market size was estimated at $9.78 billion in 2024 and is projected to reach $25.00 billion by 2030, growing at a CAGR of 16.1% from 2025 to 2030. The continued advances in validating and progressing the ABBIE technology as best in class provides a direct path for market acquisition. Coupled with a global IP portfolio, SOHM and its ABBIE technology is positioned to become a dominant technology in the global gene editing market.
